BioPharmSignal logoBioPharmSignal

Biotech News

Innoviva to Participate in Upcoming Investor Conferences

Innoviva (INVA)InnovivaCompany update

BURLINGAME, Calif. --(BUSINESS WIRE)--Sep. 2, 2026-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a

Related news

INVAInnoviva2026-02-19 13:00 EST

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

INVAInnoviva2026-08-11 20:05 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

ZNTLZentalis2026-09-02 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

ENTAEnanta Pharmaceuticals2026-09-01 11:00 EST

Enanta Pharmaceuticals to Participate in September Investor Conferences

PHARPharming Group2026-04-07 06:00 EST

Pharming Group to participate in April investor conferences

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

BCRXBioCryst Pharmaceuticals2026-04-28 11:00 EST

BioCryst to Present at Upcoming Investor Conferences

ZNTLZentalis2026-02-03 21:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

View all latest news

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

INVAInnoviva2026-09-02 12:00 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-08-11 20:05 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-18 12:00 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Stock data

Close
21.05 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States